<?xml version="1.0" encoding="UTF-8"?><meta xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns="http://www.w3.org/1999/xhtml" xmlns:xi="http://www.w3.org/2001/XInclude" http-equiv="Content-Type" content="text/html; charset=utf-8" />
<style xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:xi="http://www.w3.org/2001/XInclude" type="text/css">
   @media screen{
   .test-story-main legend{
   text-align:center;
   font-size:110%;
   font-weight:bold;
   }
   .test-story-main .nav-tabs{
   font-weight:bold;
   }
   .test-story-main .tds_obxGrpSpl{
   background:#B8B8B8;
   }
   .test-story-main maskByMediaType{
   display:table;
   }
   .test-story-main table tbody tr th{
   font-size:95%
   }
   .test-story-main table tbody tr td{
   font-size: 110%;
   }
   .test-story-main table tbody tr th{
   text-align:left;
   background:#C6DEFF;
   font-size:100%;
   }
   .test-story-main fieldset{
   text-align:center;
   }
   .test-story-main table{
   width:98%;
   border:1px groove;
   table-layout:fixed;
   margin:0 auto;
   border-collapse:collapse;
   }
   .test-story-main table tr{
   border:2px groove;
   
   }
   .test-story-main table th{
   border:2px groove;
   
   }
   .test-story-main table td{
   border:1px groove;
   
   }
   .test-story-main table thead{
   border:1px groove;
   background:#446BEC;
   text-align:center;
   }
   .test-story-main .separator{
   background:rgb(240, 240, 255);
   text-align:left;
   }
   .test-story-main table tbody tr td{
   text-align:left
   }
   .test-story-main .noData{
   background:#B8B8B8;
   }
   .test-story-main .childField{
   background:#B8B8B8;
   }
   .test-story-main .title{
   text-align:left;
   }
   .test-story-main h3{
   text-align:center;
   page-break-inside:avoid;
   }
   .test-story-main h2{
   text-align:center;
   }
   .test-story-main h1{
   text-align:center;
   }
   .test-story-main .pgBrk{
   padding-top:15px;
   }
   .test-story-main .er7Msg{
   width:100%;
   }
   .test-story-main .embSpace{
   padding-left:15px;
   }
   .test-story-main .accordion-heading{
   font-weight:bold;
   font-size:90%;
   }
   .test-story-main .accordion-heading i.fa:after{
   content:"\00a0 ";
   }
   .test-story-main panel{
   margin:10px 5px 5px 5px;
   }
   }
   
   @media print{
   .test-story-main legend{
   text-align:center;
   font-size:110%;
   font-weight:bold;
   }
   .test-story-main .nav-tabs{
   font-weight:bold;
   }
   .test-story-main .obxGrpSpl{
   background:#B8B8B8;
   }
   .test-story-main maskByMediaType{
   display:table;
   }
   .test-story-main table tbody tr th{
   font-size:90%
   }
   .test-story-main table tbody tr td{
   font-size:90%;
   }
   .test-story-main table tbody tr th{
   text-align:left;
   background:#C6DEFF;
   
   }
   .test-story-main table thead tr th{
   text-align:center;
   background:#4682B4;
   
   }
   .test-story-main fieldset{
   text-align:center;
   page-break-inside:avoid;
   }
   .test-story-main table{
   width:98%;
   border:1px groove;
   table-layout:fixed;
   margin:0 auto;
   page-break-inside:avoid;
   border-collapse:collapse;
   }
   .test-story-main table tr{
   border:2px groove;
   }
   .test-story-main table th{
   border:2px groove;
   }
   .test-story-main table td{
   border:1px groove;
   }
   .test-story-main table thead{
   border:1px groove;
   background:#446BEC;
   text-align:left;
   }
   .test-story-main .separator{
   background:rgb(240, 240, 255);
   text-align:left;
   }
   .test-story-main table tbody tr td{
   text-align:left;
   }
   .test-story-main .noData{
   background:#B8B8B8;
   }
   .test-story-main .childField{
   background:#B8B8B8;
   }
   .test-story-main .tds_title{
   text-align:left;
   margin-bottom:1%
   }
   .test-story-main h3{
   text-align:center;
   }
   .test-story-main h2{
   text-align:center;
   }
   .test-story-main h1{
   text-align:center;
   }
   .test-story-main .tds_pgBrk{
   page-break-after:always;
   }
   .test-story-main #er7Message table{
   border:0px;
   width:80%
   }
   .test-story-main #er7Message td{
   background:#B8B8B8;
   font-size:65%;
   margin-top:6.0pt;
   border:0px;
   text-wrap:preserve-breaks;
   white-space:pre;
   }
   .test-story-main .er7Msg{
   width:100%;
   font-size:80%;
   }
   .test-story-main .er7MsgNote{
   width:100%;
   font-style:italic;
   font-size:80%;
   }
   .test-story-main .embSpace{
   padding-left:15px;
   }
   .test-story-main .embSubSpace{
   padding-left:25px;
   }
   .test-story-main .accordion-heading{
   font-weight:bold;
   font-size:90%;
   }
   .test-story-main .accordion-heading i.fa:after{
   content:"\00a0 ";
   }
   .test-story-main panel{
   margin:10px 5px 5px 5px;
   }
   }
</style>
<!-- generated by TestStory_v1.xslt Version:1.0   Profile:TestStory-->
<fieldset>
	<div class="test-story-main">
		<tabset>
			<tab heading="FULL"  vertical="false">
				<div class="panel-body">
					<div class="panel-body"><table><tr><th>Description</th></tr><tr><td><p>The user responsible for the EHR configuration updates the system with a new vaccine schedule</p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Comments</th></tr><tr><td><p>No Comments</p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Pre-condition</th></tr><tr><td><p>The EHR needs to be updated with a new immunization schedule for a vaccine product.</p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Post-Condition</th></tr><tr><td><p>The updated Patient Immunization Schedule for the vaccine product is available.</p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Test Objectives</th></tr><tr><td><p><strong>Update Patient Immunization Schedule:&nbsp;</strong>The EHR or other clinical software system displays a patient&rsquo;s anticipated immunization schedule routinely and updates the patient&rsquo;s schedule when immunization guidelines change.</p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Evaluation Criteria</th></tr><tr><td><p>The EHR is able to update the patient immunization schedule for the following adult vaccine:</p><p><br></p><table border="1" cellpadding="0" cellspacing="0"><tbody><tr><td valign="top" width="111">CVX:<br></td><td valign="top" width="228">208</td></tr><tr><td valign="top" width="111">Vaccine Name:<br></td><td valign="top" width="228">Pfizer-BioNTech Covid-19 Vaccine<br></td></tr><tr><td valign="top" width="111">Agegroup 12+<br></td><td valign="top" width="228">2-dose series separated by 21 days. A series started with Pfizer-BioNTech COVID-19 Vaccine should be completed with this product.<br></td></tr><tr><td valign="top" width="111">Moderately and severely immunocompromised people:<br></td><td valign="top" width="228">Administer an additional primary dose at least 28 days after the initial 2-dose primary series. <br></td></tr><tr><td valign="top" width="111">Booster Dose:<br></td><td valign="top" width="228">Administer a booster dose at least 6 months after the last dose of a COVID-19 mRNA vaccine primary series (i.e., the 2nd dose or additional primary series dose for moderately or severely immunocompromised people).<br><ul><li>Should be given to people 18 years of age and older (use of heterologous &ndash; mix and match &ndash; booster doses is allowed; however, mRNA COVID-19 vaccines are preferred)</li><li>May be given to people 16 and 17 years of age based on their individual benefits and risks</li></ul></td></tr></tbody></table><p><br></p><p><br></p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Notes</th></tr><tr><td><p>The vendor may leverage an external tool to support vaccine schedule information. If so, the vendor should provide documentation regarding how the schedule is updated, how the EHR vendor and providers are notified of the updated schedule, and where in the EHR the modification has impact.</p><p>These codes will be used to administer the new vaccine in later test steps.&nbsp;</p><p>It is acceptable to demonstrate without saving the information, and a substitute vaccine will be used later in the testing.</p><p>Should additional content be needed to complete the new record, the vendor may supply this detail, and the tester will document such information to inform future updates.</p><p>The vendor may need to show the screens and omit the commit action. If so, a substitute vaccine may be leveraged for later steps.</p><p>The tester shall document any additional comments or concerns identified by the vendor.</p><p>The test is the ability to enter the schedule and it may not reflect the current COVID schedule.</p></td></tr></table></div><br/>
				</div>
			</tab>
			<tab heading="Description" vertical="false"><div class="panel-body"><table><tr><th>Description</th></tr><tr><td><p>The user responsible for the EHR configuration updates the system with a new vaccine schedule</p></td></tr></table></div></tab><tab heading="Comments" vertical="false"><div class="panel-body"><table><tr><th>Comments</th></tr><tr><td><p>No Comments</p></td></tr></table></div></tab><tab heading="Pre-condition" vertical="false"><div class="panel-body"><table><tr><th>Pre-condition</th></tr><tr><td><p>The EHR needs to be updated with a new immunization schedule for a vaccine product.</p></td></tr></table></div></tab><tab heading="Post-Condition" vertical="false"><div class="panel-body"><table><tr><th>Post-Condition</th></tr><tr><td><p>The updated Patient Immunization Schedule for the vaccine product is available.</p></td></tr></table></div></tab><tab heading="Test Objectives" vertical="false"><div class="panel-body"><table><tr><th>Test Objectives</th></tr><tr><td><p><strong>Update Patient Immunization Schedule:&nbsp;</strong>The EHR or other clinical software system displays a patient&rsquo;s anticipated immunization schedule routinely and updates the patient&rsquo;s schedule when immunization guidelines change.</p></td></tr></table></div></tab><tab heading="Evaluation Criteria" vertical="false"><div class="panel-body"><table><tr><th>Evaluation Criteria</th></tr><tr><td><p>The EHR is able to update the patient immunization schedule for the following adult vaccine:</p><p><br></p><table border="1" cellpadding="0" cellspacing="0"><tbody><tr><td valign="top" width="111">CVX:<br></td><td valign="top" width="228">208</td></tr><tr><td valign="top" width="111">Vaccine Name:<br></td><td valign="top" width="228">Pfizer-BioNTech Covid-19 Vaccine<br></td></tr><tr><td valign="top" width="111">Agegroup 12+<br></td><td valign="top" width="228">2-dose series separated by 21 days. A series started with Pfizer-BioNTech COVID-19 Vaccine should be completed with this product.<br></td></tr><tr><td valign="top" width="111">Moderately and severely immunocompromised people:<br></td><td valign="top" width="228">Administer an additional primary dose at least 28 days after the initial 2-dose primary series. <br></td></tr><tr><td valign="top" width="111">Booster Dose:<br></td><td valign="top" width="228">Administer a booster dose at least 6 months after the last dose of a COVID-19 mRNA vaccine primary series (i.e., the 2nd dose or additional primary series dose for moderately or severely immunocompromised people).<br><ul><li>Should be given to people 18 years of age and older (use of heterologous &ndash; mix and match &ndash; booster doses is allowed; however, mRNA COVID-19 vaccines are preferred)</li><li>May be given to people 16 and 17 years of age based on their individual benefits and risks</li></ul></td></tr></tbody></table><p><br></p><p><br></p></td></tr></table></div></tab><tab heading="Notes" vertical="false"><div class="panel-body"><table><tr><th>Notes</th></tr><tr><td><p>The vendor may leverage an external tool to support vaccine schedule information. If so, the vendor should provide documentation regarding how the schedule is updated, how the EHR vendor and providers are notified of the updated schedule, and where in the EHR the modification has impact.</p><p>These codes will be used to administer the new vaccine in later test steps.&nbsp;</p><p>It is acceptable to demonstrate without saving the information, and a substitute vaccine will be used later in the testing.</p><p>Should additional content be needed to complete the new record, the vendor may supply this detail, and the tester will document such information to inform future updates.</p><p>The vendor may need to show the screens and omit the commit action. If so, a substitute vaccine may be leveraged for later steps.</p><p>The tester shall document any additional comments or concerns identified by the vendor.</p><p>The test is the ability to enter the schedule and it may not reflect the current COVID schedule.</p></td></tr></table></div></tab>
		</tabset>
	</div>
</fieldset>